Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.0951 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CERo Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Trading on OTCQB Market
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Listing on OTC Markets
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside
Via AB Newswire
News headline image
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.